Tilray Brands (NASDAQ:TLRY) Upgraded at Roth Mkm

Roth Mkm upgraded shares of Tilray Brands (NASDAQ:TLRY) from a neutral rating to a buy rating in a research note released on Thursday, MarketBeat Ratings reports. Roth Mkm currently has $10.00 price target on the stock.

TLRY has been the subject of a number of other reports. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. TD Cowen reduced their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Finally, Canaccord Genuity Group began coverage on Tilray Brands in a research note on Tuesday, January 27th. They set a “hold” rating for the company. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tilray Brands currently has a consensus rating of “Hold” and an average price target of $11.20.

Tilray Brands Price Performance

Shares of Tilray Brands stock opened at $6.55 on Thursday. Tilray Brands has a twelve month low of $3.51 and a twelve month high of $23.20. The company has a fifty day moving average price of $7.27 and a 200 day moving average price of $10.17. The company has a current ratio of 2.79, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19. The stock has a market cap of $763.12 million, a price-to-earnings ratio of -0.48 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY) last announced its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The firm had revenue of $206.73 million during the quarter, compared to analysts’ expectations of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same quarter last year, the company posted ($0.87) earnings per share. Equities research analysts forecast that Tilray Brands will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TLRY. AQR Capital Management LLC raised its holdings in shares of Tilray Brands by 1,839.7% during the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock valued at $399,000 after acquiring an additional 575,757 shares during the period. Swiss National Bank grew its position in Tilray Brands by 6.1% during the 2nd quarter. Swiss National Bank now owns 1,928,138 shares of the company’s stock worth $799,000 after purchasing an additional 111,500 shares in the last quarter. XTX Topco Ltd purchased a new position in Tilray Brands during the 2nd quarter worth approximately $112,000. J.W. Cole Advisors Inc. raised its stake in Tilray Brands by 203.2% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after purchasing an additional 48,177 shares during the period. Finally, Cerity Partners LLC raised its stake in Tilray Brands by 98.5% during the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after purchasing an additional 45,929 shares during the period. 9.35% of the stock is currently owned by institutional investors and hedge funds.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth/MKM upgraded TLRY to Buy (new $10 price target), citing the Q3 results as a catalyst for improved sentiment—this upgrade supports near-term buying interest. Roth upgrade coverage
• Positive Sentiment: Jefferies reiterated a Buy and kept a $24 price target, pointing to strong cannabis sales and better medium‑term visibility; a high PT from a major shop increases upside narratives for investors. Jefferies note
• Positive Sentiment: Regulatory tailwind: reports that the FDA won’t enforce some CBD regulations spurred sector buying, lifting Tilray alongside peers and improving the outlook for CBD revenue. FDA/CBD coverage
• Positive Sentiment: Product/brand news — Tilray Beverages’ Shock Top launched a high‑ABV beer (High Voltage), a growth/innovation signal for the beverages segment that can help top-line recovery over time. Shock Top launch
• Neutral Sentiment: Analyst/deep-dive pieces see TLRY as improving but still mixed: commentary highlights revenue growth, international cannabis up ~73% in Q3, and narrowing losses but cautions on margins, cash flow and M&A execution. This frames TLRY as a recovery story with execution risk. Seeking Alpha analysis
• Neutral Sentiment: Zacks and other commentary call Q3 mixed—revs beat slightly and losses narrowed, but beverage weakness and margin pressure temper bullish cases. Zacks piece
• Negative Sentiment: Earnings miss: TLRY reported Q3 EPS of -$0.24 vs. consensus -$0.14 (revenue ~$206.7M vs. est. ~$201.4M). The EPS shortfall on the call raised concerns about margins and profitability despite top-line improvements. MSN earnings transcript InsiderMonkey transcript
• Negative Sentiment: ATB Cormark trimmed its price target to $9.00 and moved to sector perform, signaling more conservative near‑term expectations and adding selling pressure from cautious analysts. ATB Cormark note

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.